Authors
Latest:
Dr Jain on Baseline Differences Across Different Donor Types in MyelofibrosisTania Jain, MBBS, discusses notable differences in baseline characteristics and donor sequencing, according to a retrospective study of patient outcomes following blood or marrow transplant in 4 common donor types of myelofibrosis.
Latest:
Dr Bekaii-Saab on the Future of Treatment For Patients With GI CancerTanios Bekaii-Saab, MD, FACP, discusses the future of treatment within the gastrointestinal cancers armamentarium.
Latest:
Dr Bekaii-Saab on the Role of Liquid and Tissue Biopsies for Newly Diagnosed GI CancersTanios Bekaii-Saab, MD, FACP, discusses the role of liquid and tissue biopsies in newly diagnosed gastrointestinal cancers.
Latest:
Audience Q&A: Best Practices in Managing HER2-Amplified CRCFielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Latest:
Exciting Treatment Opportunities in mCRCClosing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.
Latest:
Future Directions: Optimizing Care Through CombinationsTanios S. Bekaii-Saab, MD, describes the future direct of clinical research into immune check point inhibitors for solid tumors, which he believes will be to explore additional combinations with targeted therapies.
Latest:
Nivolumab plus Ipilimumab vs Chemotherapy as First-line Treatment for Microsatellite Instability-High/Mismatch Repair Deficient Metastatic Colorectal Cancer: First Results of the CheckMate 8HW StudyIn his discussion of the CHECKMATE 8HW trial, Dr. Tanios Bekaii-Saab examined the efficacy of chemotherapy versus nivolumab plus ipilimumab as the initial treatment for metastatic colorectal cancer with high microsatellite instability and deficient mismatch repair.
Latest:
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in CareClosing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Latest:
Evolutions in the HER2-Amplified CRC Treatment LandscapeLooking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Latest:
Dr. Armaghany on the Utility of ctDNA in CRCTannaz Armaghany, MD, discusses the utility of circulating tumor DNA in colorectal cancer.
Latest:
Revolutionizing Prostate Cancer Care: 2023’s Transformative BreakthroughsExpert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.
Latest:
New Geriatric Assessment Tools Enhance Care of Older Adults with CancerAmid a coming storm of demographic trends signaling a sharp increase in the number of older people diagnosed with cancer in the United States, researchers are developing new geriatric assessment tools to help oncology specialists better manage this patient population.
Latest:
Dr. Siddiqi on the Role of Acalabrutinib in Frontline CLLTanya Siddiqi, MD, discusses the role of acalabrutinib as a frontline treatment for patients with chronic lymphocytic leukemia.
Latest:
Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLCTaofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer.
Latest:
Novel Treatment Approaches for SCLC and Future PerspectivesA panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
Latest:
Prognostic Significance of Post-Treatment PET/CT Following Salvage Re-irradiation of Head and Neck CancersResearchers explored the prognostic significance of PET/CT following re-irradiation in patients with head and neck cancer.
Latest:
Dr. Gangadhar on Combination Regimens for MelanomaTara C. Mitchell, MD, assistant professor of Medicine, Perelman School of Medicine at the Hospital of the University of Pennsylvania, discusses new combination regimens for patients with melanoma.
Latest:
Looking Toward the Future of CLL ManagementAn expert hematologist/oncologist highlights key takeaways for the future management of chronic lymphocytic leukemia given an evolving therapeutic landscape.
Latest:
Neuroendocrine Tumor Treatment Options Are GrowingDuring the past several years, a wealth of positive clinical trials coupled with an evolution in understanding of neuroendocrine tumors has altered the treatment landscape.
